A Potential Treatment for Pregnant Women with Hyperemesis Gravidarum.
NGM Bio has initiated its EMERALD Phase 2 Clinical Trial of NGM120 in Hyperemesis Gravidarum, also known as extreme pregnancy sickness.
Bringing patient health back in balance
We are leveraging powerful insights into human biology to develop life-changing medicines.
ngmbio
Latest News
Learn More About NGM120 and Hyperemesis Gravidarum
Supportive Clinical Data and Development Status
NGM120 has been generally well-tolerated in over 200 participants treated in clinical trials to date.
NGM’s Opportunity to Treat HG: Targeting the root cause by blocking GDF15’s activity
With higher levels of GDF15 now identified as a risk factor for HG and severe nausea/vomiting during pregnancy, NGM is advancing NGM120 as a novel approach to potentially treat this condition.
Our Mission
Our mission is to translate powerful biology into life-changing medicines.
Our vision is to make lasting clinical contributions to improve human health.
Our Pipeline
We are advancing NGM120, a GDF15/GFRAL antagonist antibody, to address two significant and distinct unmet needs, both of which are rooted in overactivation of the GDF15 pathway: hyperemesis gravidarum and cancer cachexia.
NGM120
GFRAL/GDF15 Antagonist Antibody
Hyperemesis Gravidarum
EMERALD Phase 2 Clinical Trial Underway
NGM120
GFRAL/GDF15 Antagonist Antibody
Cancer Cachexia
Phase 2 Proof-of-Concept Trial Underway
Meet our Team
At NGM, every team member plays a vital role in furthering our goals and advancing our mission to deliver life-changing medicines for patients.
Led by biology. Motivated by unmet patient needs.
